Gemcitabine for Injection IP 200mg
GEMLIEVA RTU 200 MG (Gemcitabine for Injection IP 200 mg) is a prescription anticancer medication containing Gemcitabine 200 mg, a well-established chemotherapy medicine used in the treatment of various solid tumors and advanced cancers. The term RTU (Ready-to-Use) indicates that the formulation is designed for convenient clinical administration, helping healthcare professionals prepare and deliver treatment efficiently while maintaining accuracy and safety.
Gemcitabine belongs to a class of medicines known as antimetabolites. It works by interfering with DNA synthesis in rapidly dividing cancer cells, preventing them from growing and multiplying. By disrupting the cancer cell cycle, Gemcitabine helps slow disease progression and supports effective cancer management.
Cancer develops when abnormal cells grow uncontrollably and spread to surrounding tissues or distant organs. These cancer cells depend on continuous DNA replication for survival and expansion. GEMLIEVA RTU 200 MG targets this process by incorporating itself into the DNA of malignant cells and blocking further replication, ultimately leading to cancer cell death.
GEMLIEVA RTU 200 MG is widely used in modern oncology and may be administered alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment plan.
The medicine is commonly prescribed for:
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Ovarian Cancer
Bladder Cancer
Biliary Tract Cancer
Metastatic Solid Tumors
Advanced Cancer Treatment Programs
Combination Chemotherapy Regimens
Gemcitabine has become an important part of cancer treatment worldwide because of its proven clinical effectiveness and broad range of therapeutic applications. It is frequently used in both first-line and subsequent treatment settings for several cancer types.
Manufactured under strict pharmaceutical quality standards, GEMLIEVA RTU 200 MG is designed to provide consistent quality, safety, and therapeutic performance.
Patients receiving Gemcitabine therapy typically require regular blood tests, liver and kidney function assessments, and routine medical evaluations to ensure treatment safety and effectiveness.
Due to its established role in oncology care, GEMLIEVA RTU 200 MG remains a trusted treatment option for patients undergoing chemotherapy for various cancers.
View Details
Dasatinib Tablet IP 50mg
DASALIEVA 50 MG (Dasatinib Tablet IP 50 mg) is a prescription anticancer medicine containing Dasatinib 50 mg, a targeted therapy used for the treatment of specific types of blood cancers, particularly Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Dasatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs), which work by blocking abnormal proteins that promote the growth and survival of cancer cells.
Blood cancers such as CML occur when genetic mutations cause abnormal white blood cells to multiply uncontrollably. One of the key abnormalities associated with these cancers is the formation of the BCR-ABL protein, which continuously signals cancer cells to grow and divide. DASALIEVA 50 MG targets and inhibits this protein, helping to slow disease progression and control cancer growth.
Unlike traditional chemotherapy, Dasatinib is a targeted therapy designed to specifically attack cancer-related pathways while minimizing damage to healthy cells. This targeted mechanism has made Dasatinib an important treatment option for patients diagnosed with certain forms of leukemia.
DASALIEVA 50 MG is commonly prescribed for:
Chronic Myeloid Leukemia (CML)
Newly Diagnosed Chronic Phase CML
Resistant or Intolerant CML
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Advanced Phase CML
Blast Phase Leukemia
Targeted Blood Cancer Treatment
Long-Term Leukemia Management Programs
The medicine is widely used in hematology and oncology practices and may be prescribed as first-line treatment or for patients who have not responded adequately to other therapies.
Manufactured according to stringent pharmaceutical quality standards, DASALIEVA 50 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Dasatinib therapy require regular medical monitoring, including complete blood counts, liver function tests, and clinical evaluations to assess treatment response and detect potential side effects.
Due to its proven effectiveness in leukemia management, DASALIEVA 50 MG remains an essential targeted therapy in modern cancer care worldwide.
View Details
Crizotinib Tablets 250mg
CRIZLIEVA 250 MG (Crizotinib Tablets 250 mg) is a prescription targeted anticancer medicine containing Crizotinib 250 mg, used for the treatment of specific types of advanced and metastatic cancers that carry certain genetic abnormalities. Crizotinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and is designed to block abnormal proteins that drive cancer cell growth, survival, and spread.
Cancer develops when cells acquire genetic mutations that allow them to multiply uncontrollably. In some patients with Non-Small Cell Lung Cancer (NSCLC) and other rare cancers, abnormal changes in genes such as ALK (Anaplastic Lymphoma Kinase), ROS1, or MET can stimulate continuous cancer cell growth. CRIZLIEVA 250 MG specifically targets these abnormal signaling pathways, helping slow disease progression and improve treatment outcomes.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Crizotinib is a targeted therapy that focuses on specific cancer-driving mutations. This targeted approach allows for more precise treatment and has become an important option in modern oncology.
CRIZLIEVA 250 MG is commonly prescribed for:
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
ROS1-Positive Non-Small Cell Lung Cancer
Advanced Lung Cancer
Metastatic Lung Cancer
MET-Positive Tumors (in selected patients)
Targeted Oncology Treatment Programs
Precision Cancer Therapy
Long-Term Cancer Management
Before starting treatment, doctors often perform specialized molecular testing to identify whether the patient's cancer carries the genetic alterations that make Crizotinib an appropriate treatment option.
Manufactured under stringent pharmaceutical quality standards, CRIZLIEVA 250 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Crizotinib therapy require regular medical monitoring, including blood tests, liver function assessments, vision evaluations, heart monitoring, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical benefits and targeted mechanism of action, CRIZLIEVA 250 MG remains an important treatment option in modern precision oncology worldwide.
View Details
Afatinib Tablets IP 30mg
AFALIEVA 30 MG (Afatinib Tablets IP 30 mg) is a prescription targeted anticancer medicine containing Afatinib 30 mg, used primarily for the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) that carry certain Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and works by blocking cancer-promoting signals that help tumors grow and spread.
Lung cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells contain abnormal EGFR mutations that continuously stimulate tumor growth. AFALIEVA 30 MG is specifically designed to target these mutations, helping slow disease progression and improve treatment outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Afatinib is a targeted therapy that focuses on specific molecular pathways involved in cancer development. This precision-based approach allows healthcare providers to personalize treatment according to the genetic profile of the tumor.
AFALIEVA 30 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Locally Advanced Lung Cancer
Squamous Cell Carcinoma of the Lung (selected cases)
Targeted Oncology Treatment Programs
Precision Cancer Therapy
Long-Term Cancer Management
Before initiating treatment, oncologists generally recommend molecular testing to confirm the presence of EGFR mutations and determine whether Afatinib is an appropriate treatment option.
Afatinib works by irreversibly blocking multiple members of the ErbB family of receptors, including EGFR, HER2, and HER4. By inhibiting these pathways, it reduces cancer cell growth, limits tumor progression, and promotes cancer cell death.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 30 MG is designed to provide consistent therapeutic performance, quality, and patient safety.
Patients receiving Afatinib therapy typically undergo regular monitoring, including liver function tests, kidney assessments, clinical evaluations, and treatment response assessments to ensure safe and effective therapy.
Due to its proven efficacy in EGFR-positive lung cancer, AFALIEVA 30 MG has become an important component of modern targeted cancer treatment strategies worldwide.
View Details
Afatinib Tablets IP 40mg
AFALIEVA 40 MG (Afatinib Tablets IP 40 mg) is a prescription targeted anticancer medication containing Afatinib 40 mg, a highly effective tyrosine kinase inhibitor (TKI) used in the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) associated with Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib is designed to target and block abnormal proteins that drive cancer cell growth, multiplication, and spread throughout the body.
Lung cancer is among the most frequently diagnosed cancers worldwide, and advances in molecular diagnostics have made it possible to identify genetic mutations that can be specifically targeted with precision medicines. Patients whose tumors carry EGFR mutations often benefit from targeted therapies such as Afatinib, which are developed to attack cancer cells more selectively than traditional chemotherapy.
AFALIEVA 40 MG works by irreversibly inhibiting members of the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). These receptors are involved in signaling pathways that regulate cell growth and survival. When mutated, they can cause uncontrolled cancer cell proliferation. By blocking these signals, Afatinib helps slow tumor growth, reduce disease progression, and improve clinical outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, targeted therapies focus on specific cancer-driving mechanisms. This approach allows for more personalized treatment and has become a cornerstone of modern oncology.
AFALIEVA 40 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Locally Advanced Lung Cancer
Recurrent Lung Cancer
Squamous Cell Carcinoma of the Lung (selected cases)
Precision Oncology Treatment Programs
Long-Term Targeted Cancer Therapy
Before treatment begins, patients generally undergo molecular testing to confirm the presence of EGFR mutations and determine eligibility for Afatinib therapy.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Afatinib treatment usually require regular monitoring through clinical assessments, blood tests, liver function evaluations, and treatment response reviews to ensure optimal outcomes.
Due to its proven efficacy and targeted mechanism of action, AFALIEVA 40 MG is widely recognized as an important treatment option in modern lung cancer management.
View Details
Pomalidomide Capsules 4mg
IMNOLIEVA 4 MG (Pomalidomide Capsules 4 mg) is a prescription anticancer medicine containing Pomalidomide 4 mg, an immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Pomalidomide belongs to a class of medicines known as Immunomodulatory Drugs (IMiDs) and works by helping the immune system fight cancer while also directly inhibiting the growth and survival of malignant cells.
Multiple Myeloma develops when abnormal plasma cells multiply uncontrollably within the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, and affect kidney function. Pomalidomide helps slow disease progression by targeting multiple pathways involved in cancer growth, immune regulation, and blood vessel formation that support tumor development.
IMNOLIEVA 4 MG is commonly prescribed for patients whose disease has returned after previous treatment or has become resistant to other therapies. It is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment strategies recommended by hematologists and oncologists.
Unlike conventional chemotherapy, Pomalidomide has a unique mechanism that combines direct anticancer effects with immune system modulation. This dual action makes it an important treatment option in modern multiple myeloma management.
IMNOLIEVA 4 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Advanced Plasma Cell Disorders
Combination Cancer Therapy Programs
Long-Term Hematology Treatment Plans
Immunomodulatory Cancer Treatment
Specialized Oncology Care
The medicine is widely used in modern hematology and oncology practice and has become an essential component of treatment strategies for patients with relapsed or treatment-resistant multiple myeloma.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 4 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical monitoring, including complete blood counts, liver and kidney function tests, and routine clinical evaluations to ensure optimal treatment outcomes and patient safety.
Due to its proven effectiveness and unique immunomodulatory properties, IMNOLIEVA 4 MG remains an important treatment option in advanced multiple myeloma care worldwide.
View Details
Pomalidomide Capsules 2mg
IMNOLIEVA 2 MG (Pomalidomide Capsules 2 mg) is a prescription anticancer medication containing Pomalidomide 2 mg, an advanced immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a cancer that develops in plasma cells within the bone marrow. Pomalidomide belongs to a group of medicines known as Immunomodulatory Drugs (IMiDs), which help strengthen the body's immune response against cancer cells while directly inhibiting tumor growth and survival.
Multiple Myeloma occurs when abnormal plasma cells multiply uncontrollably in the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, increase the risk of infections, and affect kidney function. Pomalidomide helps manage the disease by targeting several pathways involved in cancer cell growth, immune system regulation, and tumor development.
IMNOLIEVA 2 MG is commonly prescribed for patients with relapsed or refractory Multiple Myeloma, particularly when previous treatments have not produced the desired results or when the disease returns after earlier therapy. The medicine is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment regimens developed by hematologists and oncologists.
Unlike traditional chemotherapy, Pomalidomide offers a targeted and immune-based approach to cancer treatment. It helps activate specific immune cells, suppresses cancer cell growth, and reduces the formation of new blood vessels that tumors require for continued growth.
IMNOLIEVA 2 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Plasma Cell Disorders
Advanced Blood Cancer Management
Combination Oncology Treatment Programs
Long-Term Hematology Care
Immunomodulatory Cancer Therapy
The medicine has become an important component of modern blood cancer treatment and is widely used in specialized oncology and hematology centers worldwide.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 2 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical supervision, including blood tests, liver function monitoring, kidney assessments, and routine clinical evaluations to ensure optimal treatment outcomes.
Due to its proven clinical effectiveness in managing advanced Multiple Myeloma, IMNOLIEVA 2 MG remains a trusted option in modern cancer care.
View Details
Megestrol Tablets IP 160mg
MEGESLIEVA 160 MG (Megestrol Tablets IP 160 mg) is a prescription medication containing Megestrol Acetate 160 mg, a synthetic progestin widely used in oncology and supportive care. It is commonly prescribed for the management of certain hormone-sensitive cancers and for the treatment of loss of appetite (anorexia), significant weight loss, and cancer-related cachexia in patients requiring nutritional support.
Megestrol Acetate belongs to a class of medicines known as progestational agents. It works by influencing hormone activity within the body and helping regulate processes associated with appetite, metabolism, and cell growth. In oncology, Megestrol may be used as part of treatment strategies for selected hormone-responsive cancers, while in supportive care it is frequently prescribed to stimulate appetite and promote weight gain in patients experiencing unintended weight loss.
Cancer and chronic illnesses can often lead to poor appetite, nutritional deficiencies, and muscle wasting, which may affect overall quality of life and treatment outcomes. MEGESLIEVA 160 MG helps improve appetite, increase food intake, and support weight maintenance, making it an important supportive therapy for many patients undergoing cancer treatment or living with chronic medical conditions.
MEGESLIEVA 160 MG is commonly prescribed for:
Cancer-Related Appetite Loss
Cancer Cachexia (Cancer-Related Weight Loss)
Unexplained Weight Loss
Nutritional Support Therapy
Advanced Cancer Supportive Care
Hormone-Sensitive Breast Cancer (Selected Cases)
Hormone-Sensitive Endometrial Cancer
Long-Term Supportive Oncology Care
Appetite Stimulation Programs
The medicine may be prescribed alone or as part of a broader treatment plan depending on the patient's medical condition and therapeutic goals.
Manufactured according to stringent pharmaceutical quality standards, MEGESLIEVA 160 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Megestrol therapy should undergo regular medical evaluations to monitor treatment response, body weight, nutritional status, and overall health.
Due to its established role in appetite stimulation and supportive oncology care, MEGESLIEVA 160 MG remains an important treatment option in modern clinical practice.
View Details
Gefitinib Tablets IP 250mg
GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) is a prescription targeted anticancer medicine containing Gefitinib 250 mg, which is primarily used for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). Gefitinib belongs to a class of medications known as Tyrosine Kinase Inhibitors (TKIs) that work by blocking specific proteins responsible for the growth and spread of cancer cells.
Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for the majority of lung cancer cases worldwide. Certain patients with NSCLC have specific EGFR gene mutations that cause uncontrolled cancer cell growth. GEFLIEVA 250 MG is specifically designed to target these mutations and inhibit the signaling pathways that promote tumor development and progression.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Gefitinib provides a more precise and targeted approach to cancer treatment. By directly targeting EGFR-positive cancer cells, it helps slow tumor growth while minimizing damage to normal tissues.
GEFLIEVA 250 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Lung Cancer
Metastatic Lung Cancer
Locally Advanced NSCLC
Recurrent Lung Cancer
First-Line Targeted Therapy for Eligible Patients
Precision Oncology Treatment Programs
Long-Term Cancer Management
Before starting treatment, healthcare professionals typically perform molecular testing to confirm the presence of EGFR mutations. This helps identify patients who are most likely to benefit from Gefitinib therapy.
Gefitinib has become an important part of modern precision oncology because it specifically targets cancer-driving genetic abnormalities. It is often prescribed as a first-line treatment for eligible patients and may also be used in certain advanced-stage cancer treatment plans.
Manufactured under stringent pharmaceutical quality standards, GEFLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Gefitinib therapy usually require routine monitoring, including clinical assessments, liver function tests, blood investigations, and regular follow-up appointments to evaluate treatment response and manage potential side effects.
Due to its targeted mechanism and proven clinical benefits, GEFLIEVA 250 MG remains an important treatment option for patients with EGFR-positive lung cancer worldwide.
View Details
Capecitabine Tablets IP 500mg
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is a prescription anticancer medicine containing Capecitabine 500 mg, an oral chemotherapy medication widely used for the treatment of various types of cancer, including colorectal cancer, breast cancer, gastric cancer, and other advanced solid tumors. Capecitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells.
Capecitabine is considered a prodrug, meaning it is converted inside the body into 5-Fluorouracil (5-FU), a well-established anticancer agent. This conversion occurs more actively within tumor tissues, helping target cancer cells while reducing exposure to healthy tissues. As a result, CAPELIEVA 500 MG offers the convenience of oral administration while delivering the proven benefits of fluoropyrimidine-based cancer therapy.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. CAPELIEVA 500 MG helps slow or stop this process by disrupting DNA synthesis in rapidly dividing cancer cells, thereby reducing tumor growth and progression.
The medicine is frequently prescribed as a standalone therapy or in combination with other chemotherapy agents, targeted therapies, or radiation treatment depending on the type and stage of cancer.
CAPELIEVA 500 MG is commonly prescribed for:
Colorectal Cancer
Metastatic Colorectal Cancer
Breast Cancer
Metastatic Breast Cancer
Gastric (Stomach) Cancer
Advanced Gastrointestinal Cancers
Combination Chemotherapy Regimens
Long-Term Oncology Treatment Programs
One of the key advantages of Capecitabine is that it allows patients to receive chemotherapy treatment at home under the supervision of their oncologist, reducing the need for frequent hospital-based infusions.
Manufactured according to strict pharmaceutical quality standards, CAPELIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Capecitabine therapy require regular medical monitoring, including blood tests, liver and kidney function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven clinical effectiveness and convenient oral administration, CAPELIEVA 500 MG remains an important component of modern cancer treatment worldwide.
View Details
Abiraterone Acetate Tablets IP 500mg
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is a prescription anticancer medicine containing Abiraterone Acetate 500 mg, a targeted hormonal therapy used primarily for the treatment of prostate cancer. It is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) as part of a comprehensive oncology treatment plan.
Abiraterone Acetate belongs to a class of medicines known as androgen biosynthesis inhibitors. Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, to grow and multiply. ABIRALIEVA 500 MG works by blocking an enzyme called CYP17 (17α-hydroxylase/C17,20-lyase), which plays a crucial role in the production of androgens in the testes, adrenal glands, and tumor tissues.
By significantly reducing androgen levels throughout the body, Abiraterone helps slow the growth and spread of prostate cancer cells. This targeted mechanism has made it one of the most important advances in the treatment of advanced prostate cancer.
Unlike conventional chemotherapy, Abiraterone specifically targets hormone production pathways associated with prostate cancer progression. It is frequently prescribed alongside corticosteroids such as prednisone or prednisolone to help manage certain treatment-related effects and optimize therapeutic outcomes.
ABIRALIEVA 500 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine has become a cornerstone of modern prostate cancer treatment due to its ability to improve disease control and support long-term management strategies.
Manufactured under stringent pharmaceutical quality standards, ABIRALIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy typically undergo regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical efficacy and targeted hormonal action, ABIRALIEVA 500 MG remains an important treatment option in advanced prostate cancer care worldwide.
View Details
Abiraterone Acetate Tablets IP 25mg
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is a prescription anticancer medicine containing Abiraterone Acetate 250 mg, a targeted hormonal therapy widely used in the treatment of advanced prostate cancer. It is specifically designed to help manage prostate cancers that depend on male hormones, known as androgens, for growth and survival.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, cancer cells continue to grow even after conventional hormone-lowering treatments. ABIRALIEVA 250 MG helps address this challenge by reducing androgen production throughout the body, thereby slowing cancer progression and helping improve treatment outcomes.
Abiraterone Acetate belongs to a class of medicines called Androgen Biosynthesis Inhibitors. It works by blocking the activity of the CYP17 enzyme, which plays a crucial role in the production of testosterone and other androgens in the adrenal glands, testes, and prostate tumor tissues. By significantly reducing androgen levels, the medicine helps limit the growth and spread of prostate cancer cells.
Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, Abiraterone targets hormone production pathways associated with cancer progression. This targeted mechanism has made it an important component of modern prostate cancer treatment strategies.
ABIRALIEVA 250 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Dependent Prostate Cancer
Long-Term Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine is often used in combination with corticosteroids such as prednisone or prednisolone as recommended by healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ABIRALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy require regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted hormonal action, ABIRALIEVA 250 MG has become a trusted treatment option for advanced prostate cancer worldwide.
View Details
